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ABSTRACT  
Objectives: To determine the impact of human immunodeficiency (HIV) infection on 
rheumatoid arthritis (RA) disease activity. 
Patients & Methods: Retrospective record review of RA patients who HIV sero-
converted, compared to a HIV negative RA control group. DAS28-ESR and -CRP 
scores were collected at the initial presentation (T0), time when HIV diagnosis made 
(TH) and the last clinic visit (TL). 
Results: Forty three HIV positive RA patients were included. At TL disease activity 
was similar between the groups, despite methotrexate (MTX) being continued in only 
11.6% of the HIV group (vs. 83.7% in the control group, p=0.0002). In the HIV group, 
all clinical parameters improved except the ESR, which accounted for the significantly 
higher DAS28-ESR compared to the DAS28-CRP at TL (p=0.004). At TL only 13.9% 
HIV patients had ongoing moderate to high disease activity. 
 Conclusion: Overall disease activity improved with HIV seroconversion in spite of 
stopping MTX in the majority of patients. The DAS28-ESR overestimated disease 
activity compared to DAS28-CRP following HIV seroconversion.   
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CHAPTER 1: INTRODUCTION 
1.1. Introduction 
With the growing prevalence of human immuno-deficiency virus (HIV) in South Africa, it 
is now not an unfamiliar situation where patients with chronic medical conditions are co-
infected with HIV. The complexity of individual diseases and their overlapping 
pathophysiology makes chronic disease interaction difficult to predict an outcome and 
consequently, choosing the appropriate therapy even more difficult. Currently, there are 
only a handful of published papers describing rheumatoid arthritis (RA) and HIV co-
infection.  The controversy over the exact effect of HIV on RA is still very debatable with 
varied clinical outcomes still being described, ranging from HIV induced RA remission 
(Bijlsma et al., 1988, Lapadula et al., 1997) to ongoing active synovitis (Black and 
Madhok, 1992, Ornstein et al., 1995). 
 1.2.  Rheumatoid arthritis        
  1.2.1. INTRODUCTION 
RA is a chronic, systemic, inflammatory, autoimmune disease that primarily involves 
the peripheral joints (Scott et al., 1987), but may also have extra-articular 
manifestations. Its primary target is the synovial tissue, which is characterized by 
leucocyte infiltration followed by hyperplasia and pannus formation (Bostrom et al., 
2011). This will ultimately lead to erosion of cartilage and irreversible joint 
destruction, and if the process is left unchecked can cause significant disability due to 
functional impairment. 
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  1.2.2. EPIDEMIOLOGY 
The worldwide prevalence in the adult population is approximately 1%, with a female 
predominance (by a ratio of 3 to 1) (Gabriel, 2001), and an earlier onset in women 
frequently beginning in the childbearing years (Symmons et al., 1994). Compared to 
the African population, the prevalence of RA has been reported as approximately 
0.9% for urban black South Africans (Beighton et al., 1975), and less than <0.1% in 
the rural black population. There are studies to suggest that there is a much greater 
female prevalence (6.9:1) and a younger age of onset (commonly less than 40 years 
of age) in our African patients, as compared to than the Western world (Tikly et al., 
2003). 
  1.2.3. PATHOPHYSIOLOGY OF RHEUMATOID ARTHRITIS. 
There are multiple complex mechanisms contributing to the chronic inflammation 
seen in RA, and these mechanisms act both in parallel and sequentially within an 
affected joint (Lee and Weinblatt, 2001). The current understanding of the 
pathogenesis of the disease is still incomplete, but there is evidence to support the 
CD4 T cell playing a central role in initiating and perpetuating the chronic 
inflammation (Harris, 1990). Within the RA synovium, the T-lymphocytes form the 
bulk of the cells, more specifically the T-helper 1(Th1) CD4 cells, which upon 
activation by as yet unknown antigens; drive a pro-inflammatory process 
characterized by activation and proliferation of synovial and endothelial cells, 
recruitment and activation of additional pro-inflammatory cells, secretion of cytokines 
(tumour necrosis factor [TNF], interleukin [IL]-1, IL-2, interferon [IFN], and IL-12) and 
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proteases from macrophages and fibroblast-like synovial cells, and autoantibody 
production (Berner et al., 2000). These cytokines can then induce further controlled 
expression of other cytokines, cell adhesion molecules, immune-regulatory 
molecules, and other pro-inflammatory mediators. By comparison, Th2 CD4 cells 
down-regulate the inflammatory cascade by causing secretion of anti-inflammatory 
cytokines IL-4 and IL-5, which promote humoral immunity and are involved in atopy 
(Schulze-Koops and Kalden, 2001). Additional antigens also recognized to activate T 
cells include: Type II collagen, cartilage antigen glycoprotein (gp) -39, 
immunoglobulin (Ig) G, and citrullinated proteins and peptides (Cope et al., 1999, De 
Rycke et al., 2004, Grinnell et al., 2005, He et al., 2000).   
Other than CD4 T cells, macrophages, fibroblasts, osteoclasts, neutrophils, and B 
lymphocytes all add to the chronic inflammation. Specific antibody production 
produced by the B lymphocytes, include rheumatoid factor (RF) and anti-citrullinated 
peptide (anti-CCP) antibodies, whose presence indicates a higher rate of bone 
erosions and extra-articular manifestations. 
The hypertrophic, inflamed synovium known as the pannus eventually leads to 
cartilage destruction at the cartilage-pannus junction, via direct invasion of the 
synovial cells into the cartilage (Bostrom et al., 2011), and rarely by abscess 
formation from neutrophils and areas of rapid chondrolysis.  Associated with the 
cartilage breakdown is subchondral bone destruction, from the action of osteoclasts, 
chondroclasts together with metalloproteinase all activated by synovial cytokines. 
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  1.2.4. DIAGNOSIS  
Rheumatologists are passionate about classification criteria and nomenclature for 
various rheumatic diseases, as they help with standardisation of disease diagnosis 
and are useful in clinical research. Over the decades, multiple different „classification‟ 
criteria have been developed for RA, only to be superseded with the progressive 
improvement of criteria to update the shortcomings of previous classification 
systems.  
One of the first classification criteria for RA was proposed in 1958, by the American 
Rheumatism Association (Ropes et al., 1958), which was based on experiences of 
the committee members, a literature review of recent surveys, and case reviews of 
many hundreds of patients scattered over the United States Of America. This version 
of the classification criteria was extensively used, but as time passed and the 
knowledge of rheumatic disorders increased many forms of arthritis previously 
misdiagnosed could be separately classified. This brought about a revision of the 
criteria which would increase the sensitivity and specificity of the diagnostic criteria 
for the identification of RA, and was known as the 1987 American College of 
Rheumatology (ACR) criteria (Arnett et al., 1988).  
The latest criteria for RA, the 2010 American College of Rheumatology/European 
League Against Rheumatism (ACR/EULAR) criteria (Aletaha et al., 2010), improved 
the inadequacy of the 1987 ACR criteria‟s inability to recognise and diagnose early 
undifferentiated arthritis with an increased risk of erosive disease of RA.  
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 This study was concluded before this most recent publication and was therefore 
based on the 1987 ACR criteria (Arnett et al., 1988), which required more than 4 
criteria to be met and present for a duration longer than six weeks, then RA is the 
probable diagnosis. The criteria include: (1) Morning stiffness, lasting for more than 
one hour before maximal improvement; (2) Arthritis of 3 or more joint areas; (3) 
Arthritis of hand joints; (4) Symmetric arthritis; (5) Rheumatoid nodules; (6) Serum RF 
and; (7) radiographic changes of periarticular osteopenia with marginal erosions. 
  1.2.5. ASSESSMENT OF DISEASE ACTIVITY 
There are numerous composite formulations available to assess disease activity in 
RA, e.g. Disease Activity Score (DAS), 28-joint DAS (DAS28 – erythrocyte 
sedimentation rate [ESR] or – C-reactive protein [CRP]), Simplified Disease Activity 
Index (SDAI), and the Clinical Disease Activity Index (CDAI) (see Figure 1.1).  
 
Figure 1.1 DAS28 joint count homunculus 
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These scores provide a means of monitoring disease activity, allowing for treatment 
to be adjusted accordingly. The SDAI is the sum of the 28 swollen joint count (SJC), 
the 28 tender joint count (TJC), the patient global assessment (PGA) and the 
physician assessment of disease activity using a 10cm long visual analogue score 
(VAS), and the CRP value in mg/dl (Aletaha et al., 2005). The CDAI is similar to the 
SDAI, but without the CRP value and more emphasis on the clinical assessment. The 
initial DAS score comprised the: Ritchie articular index (joint score based on 
tenderness, where all joints are examined, but the proximal interphalangeal; 
metacarpophalangeal; metatarsophalangeal; temporomandibular; sternoclavicular; 
and acromioclavicular joints are calculated as a single unit); 44 swollen joint count; 
ESR and the PGA. Once it was established that a 28 joint count performed as well as 
more extensive joint counts, the DAS evolved into the DAS28 (Prevoo et al., 1995). 
The DAS28 scoring system, which is used at the Chris Hani Baragwanath Academic 
Hospital Rheumatology Unit, is a composite score made up of multiple variables 
including:  SJC, TJC, PGA, and either ESR or CRP value (van der Heijde et al., 
1992).  
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Formulae:  
Equation 1.1 Calculation of DAS28-ESR 
DAS28-ESR = 0.56*√TJC + 0.28*√SJC + 0.7*InESR+0.014*PGA 
 
Equation 1.2 Calculation of DAS28-CRP 
DAS28-CRP = 0.56* √TJC28 + 0.28√SJC28 + 0.36*In (CRP+1) + 0.014*PGA + 0.96. 
 
Disease activity is categorized as follows:  ≤2.6 remission, ≤ 3.2 low disease activity, 
3.2 – 5.1 moderate disease activity and ≥ 5.1 high disease activity (Aletaha et al., 
2005). 
  1.2.6. TREATMENT 
The approach to RA treatment is improving as the understanding of the 
pathophysiology evolves. The principles of treatment are to relieve pain, improve 
function, control joint inflammation and thereby reduce irreversible joint damage, and 
to prevent/treat complications, including drug complications. The modalities available 
include non-pharmacological therapy (i.e. education, physiotherapy, and 
occupational therapy), drugs and surgery. Pharmacological agents include non-
steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease modifying anti-
rheumatic drugs (DMARDs), and both synthetic and biologic DMARDs. It is vital to 
definitively diagnose RA early, as joint damage occurs early on in the disease 
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process and treatment with a DMARD should be implemented as soon as possible 
(Goekoop-Ruiterman et al., 2005). Monitoring of disease with composite scores (e.g. 
DAS28) can help with clinical decision making to achieve tight control.  
Disease-modifying anti-rheumatic drugs form the mainstay of drug treament in RA 
and can be divided into non-biologic and biologic drugs, where both classes provide 
immunosuppressive effects through different mechanisms. Synthetic DMARDs 
include chloroquine (CQ), sulfasalazine (SSZ), methotrexate (MTX), and leflunomide 
(LEF). MTX inhibits deoxyribonucleic acid (DNA) dihydrofolic acid reductase thereby 
interfering with DNA synthesis, repair and cellular replication, and if control is 
insufficient with MTX alone, other DMARDs are added to achieve tight control. MTX 
is considered the “anchor drug” in RA treatment and is continued in combination 
regimens in patients with poor disease control. Although MTX being the principal 
agent in RA treatment, there are studies to suggest that LEF and SSZ are as 
effective MTX (Donahue et al., 2008). The ACR recommendations prefer MTX and 
LEF for active disease with features of poor prognosis (Saag et al., 2008).  Biologic 
drugs target cytokines or their receptors and include the TNF inhibitors, etanercept, 
infliximab, and adalimumab, the IL-1 receptor antagonist, anakinra, the IL-6 receptor 
antagonist, tocilizumab, the CTLA4-Ig fusion protein, abatacept, and the anti-CD20 
B-cell monoclonal antibody target, rituximab. The use of DMARDs is not without 
toxicity and it is important to monitor for infections, liver toxicity, renal toxicity, bone 
marrow suppression and malignancies. The DMARD agents available at the Chris 
Hani Baragwanath Rheumatology Unit are almost exclusively the synthetic agents, 
where MTX forms the pivotal drug in most cases.  
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 1.3. Human immunodeficiency virus 
  1.3.1. OVERVIEW 
Human immunodeficiency virus is a blood-borne virus, which belongs to the family of 
human retroviruses (retroviridae) and the subfamily of lentiviruses. There are two 
distinct species of HIV, namely HIV-1 and HIV-2 subtypes, superficially similar but 
with unique replication processes. The HIV-1 subtype seems to predominate in the 
developed world (Taylor and Hammer, 2008). Infection with HIV progressively 
destroys the CD4 T cells resulting in immune impairment, increasing the risk of 
infections and malignancies, proportional to the peripheral CD4 T cell count. Disease 
can vary from asymptomatic to acquired immuno-deficiency syndrome (AIDS), which 
is defined by either the Center for Disease Control (CDC) or World Health 
Organization (WHO) staging classification (CDC, 1999, WHO, 2007).  
The worldwide incidence of HIV/AIDS, according to United Nations AIDS (UNAIDS), 
in 2010 was estimated at 33 million people, almost 1% of the global adult population 
aged 15-49 yrs. The pandemic is still highest in Africa, with an estimated 22.5 million 
or 5% of the adult population found in sub-Saharan Africa (UNAIDS, 2010).  Recent 
HIV statistics in our study population, the Gauteng province has a prevalence of 
10.3% and an incidence highest amongst females aged 25-29 years of 32.7% and 
males 30-34 years of 25.8% (Rehle et al., 2010).  
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  1.3.2. PATHOPHYSIOLOGY OF HIV 
There are various stages in the HIV life cycle, beginning with viral transmission either 
via sexual intercourse, perinatal transmission or exposure to contaminated blood.  In 
low socioeconomic regions, vaginal intercourse is responsible for 70-80% of 
HIV/AIDS cases (Adler, 2001).  Following viral transmission across a mucous 
membrane, the HIV is phagocytosed by antigen presenting cells (i.e., dendritic cells, 
macrophages) and transported to lymph nodes and peripheral blood where they are 
presented to the cell-mediated immune system, i.e., CD4 T cells. There are envelope 
proteins on the surface of the HIV, gp-120 and gp41, which bind to chemokine 
receptors on the surface of the CD4 T cells, namely C-C chemokine receptor type 5 
(CCR5) and C-X-C chemokine receptor 4 (CXCR4). After the binding of these 
receptors, it allows fusion of the membranes followed by release of HIV ribonucleic 
acid (RNA) and enzymes into the CD4 T cell. The HIV RNA is then converted to 
single strand DNA by the viral enzyme reverse transcriptase. Subsequently, the 
single strand of DNA is then replicated by host cell enzymes into double stranded 
HIV DNA which is taken up into the host cell nucleus and is integrated into CD4 T cell 
DNA.  The host cell then produces HIV RNA and HIV proteins, which are assembled 
in the cytoplasm of the host cells into virions which bud off from the cell membrane 
forming viruses that can infect other CD4 T cells (Cohen et al., 2011).  
The consequence of HIV infection is progressive damage to immune system, 
specifically cell-mediated immunity, but humoral immunity is also affected. The HIV 
targets the CD4 T cells with an inversion of the normal CD4/CD8 T cell ratio 
(Schechter et al., 1987). Contributing to the impaired cell-mediated immunity is the 
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cytokine dysregulation, with a shift from Th1CD4 to Th2 CD4 predominant cytokines. 
Therefore, there is a decrease in pro-inflammatory cytokines: IL-2; IFN and TNF; and 
an increase production of anti-inflammatory cytokines: IL-4; IL-5 (Clerici and Shearer, 
1993).  Humoral immunity derangement is characterized by B cell hyperplasia with 
the secretion of antibodies and a consequent hypergammaglobulinemia, especially 
IgG and IgA. 
  1.3.3. DIAGNOSIS 
The available tests to diagnose HIV include antibody testing (rapid antibody test, 
enzyme-linked immunosorbent assay [ELISA], and Western blot assay) and testing 
for HIV itself (polymerase chain reaction [PCR] and culture). Diagnosis of HIV can be 
confirmed in high prevalence areas (>10% incidence) with two positive rapid antibody 
or ELISA tests, according to the WHO criteria (Martin and Sim, 2000). The 
investigation most often used in our clinic is the ELISA, which is a serological test 
used to detect anti-HIV IgG/IgM antibodies.  
  1.3.4. TREATMENT 
After HIV seroconversion, patients should be referred to a clinician with HIV expertise 
as this has proven to offer better outcomes for the patient (Kitahata et al., 1996). The 
principal therapy to prevent immune deterioration is to initiate highly active anti-
retroviral therapy (HAART), and prophylaxis for opportunistic infections should also 
be considered. The primary goals for initiating HAART are to: reduce HIV-associated 
morbidity and mortality; restore immunologic function; suppress plasma HIV viral 
load; and to prevent HIV transmission. The WHO guidelines have recently been 
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amended following positive results with earlier HAART initiation trials (Severe et al., 
2010, Sterne et al., 2009), and now advocate initiation with HAART when the CD4 
count is less than 350cells/ µL (WHO, 2010). Until recently, HAART was initiated only 
when the patient CD4 count was less than 200cells/ µL in the South African state 
sector. However, these guidelines have recently changed to include early initiation of 
HAART in pregnant women and patients co-infected with tuberculosis with a CD4 
count <350cells/ µL, initiation if WHO stage IV, and if proven multi-drug 
resistant/extreme-drug resistant tuberculosis irrespective of CD4 count.   
 
 1.4. Rheumatoid arthritis and HIV co-infection 
As mentioned previously, the controversy over the exact effect of HIV on RA is still 
debatable. There are only a handful of published case reports describing the HIV co-
infection in RA patients, with various outcomes observed and the issue of DMARD 
treatment being a continuously problematic question. 
 
The first case described was in a 60 year old Dutch man who presented in 1985 with 
a severe polyarthritis, morning stiffness for longer than 2 hours, weight loss (8kg), 
elevated ESR of 51mm/hr, RF negative, no erosions present on x-rays, and a 
subcutaneous nodule biopsied which showed an inner necrotic core with destroyed 
collagen and fibrin with a palisade arrangement of mononuclear cells (Bijlsma et al., 
1988). Definitive RA was diagnosed and he was started on intramuscular gold to 
which he responded as evident by a decrease in the number of affected joints, weight 
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gain and a fall in ESR to 12mm/hr. The following year his physical condition 
deteriorated and he now had clinical evidence of oral candida, generalized 
lymphadenopathy, hepatosplenomegaly with positive serology for hepatitis B, 
cytomegalovirus, Epstein-Barr virus, and a positive ELISA for HIV. However, despite 
his deteriorating physical condition, there was no evidence of active synovitis, and 
thus, the question arose “Does AIDS „cure‟ rheumatoid arthritis?”   
 
A further case was that of a American 63 year old female who diagnosed with RA in 
1983 after presenting with a symmetrical polyarthritis affecting the small joints of the 
wrist and hands, associated with morning stiffness, and a positive RF (Calabrese et 
al., 1989). She was initially doing well on aspirin and intermittent injections of 
adrenocorticotropic hormone, until June 1984 when she was admitted for a week with 
fever, pharyngitis, diarrhoea, abdominal cramping, macular rash and 
lymphadenopathy. From August to October 1984 she complained of „new‟ sicca 
symptoms and her serology was repeated revealing a positive RF titre (1:5000), 
positive ANA titre (1:640), and she was then diagnosed with Sjögren‟s syndrome and 
Systemic lupus erythematosus and was initiated on aspirin and hydroxychloroquine. 
In 1985 she consulted a second rheumatologist who diagnosed RA with Felty‟s 
syndrome and Sjögren‟s syndrome, based on evidence of increasing sicca 
symptoms, fatigue, generalised lymphadenopathy, no active synovitis at that time, 
positive RF, positive ANA, and cortical bone erosions of the metacarpophalangeal 
joints on repeated x rays. She was continued on hydroxychloroquine. Her husband 
was diagnosed HIV positive in 1987, following a contaminated blood transfusion he 
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received in 1984. Later in 1987, she tested HIV positive, had no active synovitis, but 
persistent sicca symptoms that lead to a salivary gland biopsy that was consistent 
with Sjögren‟s syndrome. 
 
A 58 year old American man diagnosed with RA, fulfilling all 7 of the 1987 ACR 
criteria, had been receiving treatment with cyclophosphamide and corticosteroids for 
rheumatoid vasculitis, until he was diagnosed HIV positive by ELISA and Western 
blot after presenting with oral candidiasis and Pneumocystis carnii pneumonia (Kerr 
and Spiera, 1991). Despite his immunosuppression, it was noted that he continued to 
have active joint disease throughout his illness.  
In 1986, a 28 year old HIV positive Englishman presented with arthritis of his knees 
and feet, which developed into a RF negative symmetrical polyarthritis involving the 
small joints of the hands as well, and associated with morning stiffness (Jaffer, 1991). 
He was found to be HLA-B27 positive, but there was no report of backache, or 
evidence of psoriasis. The patient was diagnosed with RA and was treated 
unsuccessfully with NSAIDs and steroids, with the eventual development of 
periarticular osteopenia and erosions in keeping with his diagnosis. His unremitting 
active synovitis continued until his death from an upper gastrointestinal bleed 
secondary to Kaposi‟s sarcoma. 
 
In January 1991, a 48 year old female heroin user was admitted into New York City 
Hospital with asthma, but also reported symmetrical joint pains (involving knees, 
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hands, and wrists) with a history of morning stiffness and diffuse joint swelling 
(Ornstein et al., 1995). She had previously being diagnosed as RA after having a 
positive RF and typical x-ray changes. Her current therapy consisted of steroids and 
NSAIDs, as she developed a rash secondary to intramuscular gold. Later that year 
she was admitted and treated for pneumocystis carnii pneumonia. At that time she 
was tested for HIV and found to have a reactive result, and CD4 count was 
250cells/µL. She was started on HAART and continued on steroids with 
trimethoprim/sulfamethxazole; however there was ongoing polyarthritis with 2 hour 
long morning stiffness. Her arthritis continued unabated and by 2004 she had 
developed a symmetrical deforming polyarthritis involving her hands and wrists with 
active synovitis and x-rays revealing joint space narrowing with erosions.  She was 
started on hydroxychloroquine, however active synovitis of her hands persisted. 
 
In 2005, a 45 year old Spanish women, known to be HIV positive since 1999 on 
HAART, presented with a polyarthritis and established hand deformities, morning 
stiffness for 2 hours, ESR of 75mm/hr, CRP was 48 mmol/L, CD4 count 422 cells/µL, 
polyclonal hypergammaglobulinemia, and positive RF titre (1:5000) (Azeroual et al., 
2008). She was started on NSAIDs and hydroxychloroquine and clinical remission 
was achieved at follow up. Interestingly, RA was diagnosed after 6 years of HIV 
infection and her arthritis was controlled with minimal DMARD usage. But once her 
CD4 count reached normal levels, it was noted that her RA symptoms returned, thus 
immune reconstitution resulted in active RA disease.  
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The above case reports demonstrate the complexity of the RA and HIV relationship 
and only by re-examining their individual pathophysiologies can we hope to 
understand the combined disease interaction. 
 
The RA disease process is characterised by an inflamed joint mediated by a high 
proportion of T-lymphocytes, of which the CD4 T cells predominant with an increase 
of Th1 cytokines. Notable Th1 CD4 cytokines are IL-1; IL-6 and TNF-α, which initiate 
a pro-inflammatory destructive process (Bingham, 2002). Conversely, HIV causes an 
immunosuppressive state mainly through the destruction of CD4 T cells and is 
associated with other chronic immune changes such as failure of the cytotoxic T cells 
to inhibit viral replication, apoptosis, nonspecific B cell proliferation with an associated 
hypergammaglobulinemia, destruction of natural killer cells and a cytokine shift from 
pro-inflammatory to anti-inflammatory. It has been postulated that this cytokine shift 
from Th1 cell to Th2 cell dependant cytokines may be responsible for HIV induced 
RA remission (Wegrzyn et al., 2002).  The Th2 CD4 cytokines include IL-4, IL-10, 
which are mainly anti-inflammatory and are responsible for activation of the humoral 
immune response, resulting in non-specific B cell proliferation and the 
hypergammaglobulinemia. Importantly, previous studies have shown an elevated 
ESR is associated with high level of plasma proteins (Talstad et al., 1983), and thus, 
an elevated ESR may affect the DAS28-ESR score but not the DAS28-CRP. The Th2 
cytokine profile which predominates in HIV infected individuals may reflect why these 
patients have decreased disease activity. However, this may not be the only scenario 
as T cell independent factors, such as autonomous fibroblast activation, may be 
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responsible for ongoing inflammation and therefore remission might not be the 
obvious outcome.  
 
Another complex issuing facing HIV positive patients with RA is the concern of added 
immunosuppressive therapy. There is limited information concerning the safe use of 
MTX in these patients and early reports with the use of MTX in psoriatic arthritis 
showed an increase in the incidence of opportunistic infections and accelerated HIV 
disease (Duncan et al., 1998, Maurer et al., 1994), but later reports have been more 
promising (Maurer et al., 1994). Currently, no agreement exists as for the continual 
treatment of these patients and it has thus been the decision of Chris Hani 
Baragwanath Rheumatology Unit to stop MTX in all RA patients, especially those 
with a CD4 count < 100cells/µL, and switch them to either: SSZ, CQ, or a 
combination of the two or no treatment in the case of clinical remission. 
  
There are however 4 cases in the literature reporting success with the use of biologic 
agents. Aboulafia et al reported on the benefit of etanercept in a HIV positive patient 
with psoriatic plaques and arthritis not on MTX (Aboulafia et al., 2000). Gaylis et al 
described improvement in reactive arthritis symptoms in a HIV patient refractory to 
NSAIDs  treated with infliximab (Gaylis, 2003). Bartke et al had a similar patient with 
HIV and psoriatic arthritis having significant improvement of symptoms with infliximab 
(Bartke et al., 2004). Finally Kaur et al reported improvement in disease activity with 
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the use of etanercept in a patient failing combined therapy including CQ, SSZ and 
corticosteroids (Kaur et al., 2007).  
 
 1.5. Aim of the study 
In the absence of any studies in a HIV endemic region, like South Africa, the aim of 
this presentation was to assess the impact of HIV infection on RA clinical activity 
seen at Chris Hani Baragwanath Academic Rheumatology Unit. The primary 
objective was to assess the changes in disease activity with HIV seroconversion, and 
the secondary objective was to compare the difference between DAS28-ESR and 
DAS28-CRP following seroconversion. 
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CHAPTER 2:  PATIENTS AND METHODS 
 2.1. Patients 
Inclusion criteria for the study group, henceforth called the HIV group, included 
patients 1) fulfilled criteria for RA (Arnett et al., 1988), 2) who initially tested HIV 
negative at the time of RA diagnosis and subsequently contracted HIV infection, and 
3) in whom disease activity parameters (SJC, TJC, PGA, ESR, CRP) had been 
recorded since 1994. Exclusion criteria included 1) incomplete data, and 2) patients 
who presented simultaneously with RA and HIV.  A HIV group was matched to a 
control group for sex and age (+/-5 years). 
 2.2. Methods 
Data from three specific periods was collected to analyse the impact of HIV on RA, 
i.e. T0 - time of initial RA diagnosis, TH – first visit after HIV diagnosis, and TL - the 
last clinic visit up until 31/12/2008. Data abstracted from case records included: SJC, 
TJC, PGA based on the visual analogue score, DAS28-ESR, DAS28-CRP, CD4 
counts, chronic infections, malignancies, and medications. RF was assayed by 
nephelometry (Siemens Healthcare Diagnostics, BN Prospec Nephelometer, Newark, 
USA) and a value greater than 15 IU/ml was considered positive.  
HIV testing was routinely performed annually in the clinic because of the high 
incidence of HIV in the community, the unknown risk of HIV and continued MTX 
treatment, or when there was a clinical suspicion. 
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  2.2.1 CALCULATION AND EVALUATION OF DISEASE ACTIVITY  
  
The DAS28-ESR and DAS28-CRP formulas were used to calculate disease activity. 
Disease activity was categorized as follows:  ≤2.6 remission, ≤ 3.2 low disease 
activity, 3.2 – 5.1 moderate disease activity and ≥ 5.1 high disease activity.  (See 
Equation 1.1 and 1.2) 
  2.2.2. STATISTICS 
Data was captured on a Microsoft Excel spreadsheet and then transferred to 
GraphPad InStat (version 3) software, which was used for statistical analysis. To 
compare continuous variables the Student‟s T-test was used, and for categorical 
variables, the Chi-square test or the two-tailed Fisher‟s exact test was applied. 
Correlation of continuous variables was analysed by using the Pearson‟s correlation 
test. A p-value of <0.05 was considered significant.  
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CHAPTER 3:  RESULTS 
 3.1. HIV group 
A total 1712 had RA and documented disease activity parameters since 1994 in the 
out-patient records. Of these 85 patients were HIV positive, but only 43 of those met 
the inclusion criterion of having contracted HIV after the diagnosis of RA was made 
(see Figure 3.1).  Hence, the overall prevalence of HIV in this cohort of RA patients 
was 4.9%. 
 
 
 
 
Figure 3.1 HIV prevalence in RA patients 
 
Of the 43 patients, 39 (90.7%) were female and 4 males (9.3%) with a mean(SD)  
age of 47.1(10.1) years (range 23-65), mean(SD) age of RA diagnosis  36.4 (12.1) 
years (range 8-60), mean(SD) RA disease duration  10.5 (8.4) years (range 1-38), 
mean(SD) HIV duration of 2.9 (2.0) years (range0-8), and the mean(SD) RF at T0 
was 415 (839) IU/ml (see Table 3.1). At T0, only 20 (46.5%) patients had been 
initiated on MTX based therapy, but this number increased to a total of 34 (79%) 
patients on MTX treatment by TH.  At this point, TH, DMARD therapy was de-
1712 RA Patients 
43 Patients sero-
converted during their 
illness 
42 Patients presented 
initially with HIV and 
RA 
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escalated to reduce the risk of opportunistic infections due to the combined 
immunodeficiency caused by HIV infection and MTX. Methotrexate treatment was 
stopped in all but 5 patients. Patients were continued on other DMARDs, like SSZ 
and CQ. Five patients remained on MTX in spite of HIV seroconversion. Six patients 
were started on HAART with a mean (SD) duration of 1.5 (1.2) years treatment, 
range (6 months to 4 years). 
 
Table 3.1 Demographic table comparing HIV and control group 
 HIV Group 
(n=43) 
Control Group 
(n=43) 
p Valve 
Mean (SD) age in years  
 
47.1 (10.1) 45.7 (8.0) NS 
Mean (SD) age of RA 
diagnosis in years. 
36.4 (12.1) 38.5 (8.0) NS 
Mean (SD) RA disease 
duration in years 
10.5 (8.4) 7.1 (3.8) 0.02 
Mean (SD) HIV disease 
duration in years 
2.9 (2.0) - - 
RF (SD) IU/ml 
 
414.7  (838.93) 446.54 (650.89) NS 
% RF positive at baseline 
 
88.3% 74.4% - 
NS = Not significant; RA = Rheumatoid arthritis; RF = Rheumatoid factor. 
 
As shown in Table 3.2 and Figure 3.2, all markers of disease activity and the 
composite DAS28-ESR and DAS28-CRP scores, except the ESR, decreased 
significantly from T0 to TH. There was a numerical increase in the ESR, but this did 
not reach statistical significance. There was a further decline in PGA, DAS28-ESR, 
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and DAS28-CRP from T0 to TH, in spite of the majority, 29 of 34 patients (85%) 
coming off MTX. 
Table 3.2 Summary of HIV group results 
Variable  To 
mean (SD) 
TH 
mean (SD) 
p value * TL 
mean (SD) 
p value ** 
SJC 5.5 (4.3) 0.9 (1.8) <0.0001 0.6 (1.7) NS 
TJC 8.1 (5.3) 2.0 (4.1) <0.0001 0.8 (2.3) NS 
PGA 52.4 (22.9) 24.4 (19.8) <0.0001 15.5 (17.4) 0.04 
ESR 41.7 (25.4) 47.0 (30.7) NS 50.5 (34.7) NS 
CRP 37.1 (40.1) 12.6 (15.8) 0.002 12.3 (12.0) NS 
DAS28-
ESR 
5.2 (1.3) 3.4 (0.9) <0.0001 2.9 (0.9) 0.01 
DAS28-
CRP 
4.9 (1.1) 2.6 (1.0) <0.0001 2.2 (0.8) 0.02 
*To vs. TH; ** TH vs. TL; T0 = Time of initial RA diagnosis; TH = Time when HIV diagnosis made; TL = 
Time of last clinic visit; SJC = Swollen joint count; TJC = Tender joint count; PGA = Patient global 
assessment; ESR = Erythrocyte sedimentation rate; CRP = C-reactive protein; DAS28 = Disease 
activity score 28 joint count; NS = Not significant. 
 
Table 3.3 Summary of Remission in the HIV group  
 DAS28-ESR 
Remission (≤2.6) 
DAS28-CRP 
Remission (≤2.6) 
p value 
To 
 
2/43 2/43 NS 
TH 
 
7/43 23/43 0.0006 
TL 
 
11/43 32/43 0.0001 
T0 = Time of initial RA diagnosis; TH = Time when HIV diagnosis made; TL = Time of last clinic visit; 
ESR = Erythrocyte sedimentation rate; CRP = C-reactive protein; DAS28 = Disease activity score 28 
joint count; NS = Not significant. 
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At TH DAS28-ESR (SD) showed moderate disease activity with a mean of 3.4 (0.9) 
when compared to DAS28-CRP (SD) mean of 2.6 (1.1), indicating remission. At TL, 
DAS28-ESR (SD) had a mean of 2.9 (0.9) reflecting low disease activity and DAS28-
CRP (SD) mean of 2.2 (0.8) indicating remission (See Table 3.2). Moreover, there 
was no difference in the proportion of patients in remission as compared by the ESR 
and CRP at T0 (see Table 3.3), but at both TH and TL, the percentage of patients in 
remission was significantly higher as measured by the DAS28-CRP compared to the 
DAS28-ESR. When DAS28-ESR was compared to DAS28-CRP at each point, there 
was no statistical difference at T0 (p=0.36), but DAS28-ESR was significant higher at 
TH (p=0.0005) and TL (p=0.004), being 31.8% higher than DAS-28-CRP at TL. 
Graphic representation shows the progressive divergence between the DAS28-ESR 
and DAS28-CRP scores with time, and that the DAS28-ESR based score 
overestimated disease activity at each point compared to DAS28-CRP (See Figure 
3.3).  
In the 31 patients in whom CD4 counts were available at TH the mean (SD) count 
was 414.7 (201.17) cells/µl and at TL the mean (SD) CD4 count in the 36 patients in 
whom there were results was 390.7 (293.7) cells/µl. Subgroup analysis comparing 
CD4 counts in those patients who had achieved at least low disease activity (n=30) to 
those who continued to have moderate to high disease activity (n=6) showed no 
statistical difference (mean (SD) 419.1 [299.7] vs. 213.6 [103.7], respectively).  
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Only 6 patients had been commenced on HAART with a mean (SD) duration of 1.6 
(1.3) years. No change in disease activity had been noticed in response to therapy. 
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T0 = Time of initial RA diagnosis; TH = Time when HIV diagnosis made; TL = Time of last clinic visit; 
SJC = Swollen joint count; TJC = tender joint count; PGA = Patient global assessment; ESR = 
Erythrocyte sedimentation rate; CRP = C-reactive protein; DAS28 = Disease activity score 28 joint 
count. 
 
Figure 3.2 Changes in disease activity markers in the HIV group over time 
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Figure 3.3 Changes in DAS28 scores in the HIV group over time 
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 3.2. Control group 
There were 43 patients in the control group with a mean (SD) age of 45.7(8.0) years, 
mean (SD) age of RA diagnosis of 38.5 (8.0) years, and a mean (SD) RA disease 
duration of 7.1(3.8) years (see Table 3.1). The control groups‟ SJC, TJC, PGA, CRP, 
ESR, were compared according to two time periods under review, i.e. T0 - time of 
initial RA diagnosis, and TL - the last clinic visit up until 31/12/2008.   
At T0, 19 (44.2%) patients had been initiated on MTX based therapy, and this 
increased to 36 (83.7%) patients on MTX treatment by TL (see Table 3.8). All results, 
including the DAS28-ESR and DAS28-CRP, showed significant improvement 
between the two data capture periods (See Table 3.4 and Figure 3.4). The RF (SD) 
of 35 (81.4%) patients at T0 was 446.5 (650.89) IU/ml and at TL only 17 (40%) of 
patients had a recorded RF (SD) which was 307 (660.8) IU/ml, a non significant 
change. 
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Table 3.4 Summary of control group results 
 Variable  T0 
mean(SD) 
TL 
mean(SD) 
p value  
SJC 5.1.( 3.6) 1.2(1.5) <0.0001 
TJC 7.2(6.0) 1.6(2.8) <0.0001 
PGA 50.0(16.3) 27.3(18.7) <0.0001 
ESR 41.2(28.2) 24.4(15.2) 0.0016 
CRP 34.2(44.9) 13.4(12.9) 0.0139 
DAS28-ESR 5.1(1.1) 3.1(1.0) <0.0001 
DAS28-CRP 4.7(1.0) 2.8(1.0) <0.0001 
T0 = Time of initial RA diagnosis; TL = Time of last clinic visit; SJC = Swollen joint count; TJC = Tender 
joint count; PGA = Patient global assessment; ESR = Erythrocyte sedimentation rate; CRP = C-
reactive protein; DAS28 = Disease activity score 28 joint count. 
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Figure 3.4 Changes in DAS28 scores in the control group over time 
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3.3. Comparison between the study and control group 
The only significant difference between the two groups at T0, was the mean (SD) 
disease duration with the HIV group having a mean of 10.5 (8.4) and the control 
group mean of 7.1 (3.8) (See Table 3.1). Comparison of the disease states at T0 
revealed no significant differences, whether the DAS28-CRP or the DAS28-ESR 
calculation was used (see Table 3.5). At TL most comparisons between the HIV and 
control groups resulted in non-significant values, expect the ESR, PGA, and the 
DAS28-CRP. Due to improving disease activity in the HIV group, the PGA scores 
also improved significantly more than the control group. A key figure distinguishing 
the two groups was the DAS28-CRP, which revealed a mean (SD) in the HIV group 
of 2.2 (0.8), remission, compared to control group mean of 2.8 (1.0), active disease. 
This value is significant and represents remission in the HIV group without DMARD 
therapy compared to active disease in the control group on therapy. An increasing % 
difference between the DAS28-ESR and DAS28-CRP was noted with time; however, 
it was more marked in the HIV group than the control group. The initial % difference 
at T0 was 3% for HIV group and 4% for the control group, but then at TL the HIV 
group was 7% and the control group was 3%. There was clearly an increase 
divergence between the DAS28-ESR and DAS28-CRP valves with time which 
accounted for the widening % difference, further indication that the DAS28-ESR was 
overestimating disease activity and was being influenced by additional factors other 
than RA inflammation. The comparison of the number of patients in different disease 
category states, based on either the DAS28-ESR or –CRP, was not statistically 
significant (see Table 3.6 and 3.7). 
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A vital consideration when interpreting these results is to take into account the 
differences in DMARD trends at the different time intervals. At T0, 20 (46.5%) HIV 
patients and 19 (44.2%) control patients were on MTX, a non significant difference. 
Similarly at TH, there was no significant difference in the usage of MTX in the HIV 
group (before de-escalation of treatment), compared to the DMARD use in the control 
group at TL. However, following the diagnosis of HIV infection, the majority of patients 
in the HIV group came off MTX, and only 5 patients remained on the drug at TL, 
compared to the 36 (83.7%) patients in the control group (p=0.0002) (see Table 3.8). 
 
Table 3.5 Comparison between the HIV and control group 
 Variable  T0HIV 
mean 
(SD) 
T0Control 
mean (SD) 
p value 
* 
TL HIV 
mean 
(SD 
TL Control 
mean 
(SD) 
p value 
** 
SJC 5.5(4.3) 5.1.( 3.6) NS 0.6 (1.7) 1.2(1.5) NS 
TJC 8.1(5.3) 7.2(6.0) NS 0.8 (2.3) 1.6(2.8) NS 
PGA 52.4(22.9) 50.0(16.3) NS 15.5(17.4) 27.3(18.7) 0.013 
ESR 41.7(25.4) 41.2(28.2) NS 50.5(34.7) 24.4(15.2) <0.0001 
CRP 37.1(40.1) 34.2(44.9) NS 12.3(12.0) 13.4(12.9) NS 
DAS28-
ESR 
5.2 (1.3) 5.1(1.1) NS 2.9 (0.9) 3.1(1.0) NS 
DAS28-
CRP 
4.9 (1.1) 4.7(1.0) NS 2.2 (0.8) 2.8(1.0) 0.06 
*T0HIV vs. T0Control; ** TLHIV vs. TL Control; T0 = Time of initial RA diagnosis; TL = Time of last clinic 
visit; SJC = Swollen joint count; TJC = Tender joint count; PGA = Patient global assessment; ESR = 
Erythrocyte sedimentation rate; CRP = C-reactive protein; DAS28 = Disease activity score 28 joint 
count; NS = Not significant. 
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Table 3.6 DAS28-CRP comparison between the HIV and control group with respect 
       to disease activity categories 
 T0 
Number of patients (%) 
TL 
Number of patients (%) 
DAS28-CRP 
scores 
HIV 
group 
Control 
group 
p value HIV 
group 
Control 
group 
p value 
≥ 5.1 20 (46.5) 14 (32.5) NS 2 (4.6) 1 (2.3) - 
≥3.2 – < 5.1 14 (32.5) 23 (53.4) NS 4 (9.3) 12 (28) NS 
>2.6 – < 3.2 1 (2.3) 2 (4.6)  - 3 (7) 7 (16.2) NS 
≤ 2.6  2 (4.6) 0 - 32 (74.4) 23 (53.4) NS 
T0 = Time of initial RA diagnosis; TL = Time of last clinic visit; DAS28 = Disease activity score 28 joint 
count; NS = Not significant. 
 
Table 3.7 DAS28-ESR comparison between the HIV and control group with respect 
       to disease activity categories 
 T0 
Number of patients (%) 
TL 
Number of patients (%) 
DAS28-
ESR 
scores 
HIV 
group 
Control 
group 
p value HIV 
group 
Control 
group 
p value 
≥5.1 26 (60) 20 (46.5) NS 3 (7) 2 (4.6) NS 
≥3.2 – <5.1 11 (25.6) 21 (48.8) NS 14 (32.5) 13 (30.2) NS 
>2.6 – < 3.2 2 (4.6) 1 (2.3) -  13 (30) 11 (25.6) NS 
≤ 2.6  2 (4.6) 1 (2.3) NS 11 (25.6) 17 (39.5) NS 
T0 = Time of initial RA diagnosis; TL = Time of last clinic visit; DAS28 = Disease activity score 28 joint 
count; NS = Not significant. 
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Table 3.8 Comparison of MTX treated patients between groups at different time  
      points 
 HIV Group 
Number of patients (%) 
Control Group 
Number of patients 
(%) 
p Value 
 T0 TH TL T0 TL * ** *** 
MTX  20 (46.5) 34 (79) 5 (11.6) 19 (44.2) 36 (83.7) NS NS 0.0002 
*To HIV vs. T0 Control; ** TH HIV vs. TL Control; ***TL HIV vs. TL Control; T0 = Time of initial RA 
diagnosis; TH = Time when HIV diagnosis made; TL = Time of last clinic visit; NS = Not significant; MTX 
= Methotrexate. 
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CHAPTER 4:  DISCUSSION 
In this present study, of the 1712 RA patients, 85 were HIV positive reflecting a 
prevalence of 4.9% HIV infection in this group, which is similar to the 5% HIV burden 
reported to affect the sub-Saharan adult population (UNAIDS, 2010). The RA disease 
activity improved after HIV seroconversion, and the DAS28-ESR proved to be a less 
reliable measure of disease activity because of the non-specific increase in ESR. As 
discussed earlier, previous case reports have reported various outcomes, but this 
study has shown significant overall clinical improvement in disease activity. 
  
The female to male ratio in the HIV positive group of 9:1 is much higher than the 5:1 
reported previously in RA in this population. These findings again highlight the 
burden of HIV being disproportionally higher in South African females as shown 
previously in the general population (Rehle et al., 2010). Both the HIV and control 
groups had a mean age on RA disease onset under the age of 40. This is in keeping 
with previous studies in the developing world, including Africa, and is thought to be 
related to an overall lower life expectancy (Kalla and Tikly, 2003, Tikly et al., 2003). 
 
The HIV and control groups were matched for age and sex, and had similar disease 
activity at initial presentation, the vast majority of whom had moderate to high 
disease activity. These findings are consistent with recent studies in the same 
population and other Sub-Saharan African populations (Mody and Meyers, 1989, 
Ndongo et al., 2009), showing that patients attending the Chris Hani Baragwanath 
35 
 
Academic Hospital frequently have severe disease (Hodkinson et al., 2011). This is 
at odds with earlier studies in other parts of sub-Saharan Africa, where RA is 
considered to run a mild course (Adebajo and Reid, 1991).   
 
On follow-up, both the HIV and control groups improved with treatment. Despite the 
fact only a minority of patients in the HIV group were on MTX at last visit (11.6 % vs. 
83.7% in the control group, p=0.0002), the HIV group faired significantly better with 
respect to the PGA and a trend towards lower overall disease activity, as measured 
by the DAS28-CRP.  A higher proportion of patients in the HIV group achieved 
disease remission compared to the control group (74.4% vs. 53.4%), although the 
difference again was not statistically significant. These findings are consistent with 
the earlier anecdotal reports of RA disease activity declining with HIV infection 
(Bijlsma et al., 1988, Calabrese et al., 1989, Lapadula et al., 1997).  
 
It is not clear from the present study, what the mechanism is for the improvement in 
disease activity in the HIV group. Although the CD4 count was low in the HIV patients 
in whom it was taken, there was no clear relationship between the CD4 count and the 
decline in disease activity. Moreover, there was no further significant decline in the 
CD4 count between TH to TL, although disease activity declined significantly during 
that period. Previous studies targeting CD4 T-lymphocytes have shown only modest 
improvement in disease activity (Scheerens et al., 2011). The pathophysiology of RA 
and HIV is complicated and why some patients have ongoing joint inflammation 
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despite being immuno-suppressed, supports work regarding independent T-
lymphocyte functioning (Bartok and Firestein, 2010). Conversely, no significant 
increase in disease activity was noted in the 6 patients who were started on HAART. 
However, there have been isolated case reports of RA disease flares occurring on 
commencing HAART, possibly as part of an immune reconstitution (Azeroual et al., 
2008, Ornstein et al., 1995).  
 
Although the vast majority of patients in the HIV group did well, a small proportion 
continued to have moderate to high disease activity at TL, based on the DAS28-CRP. 
Given that MTX affects both T cell numbers and function (Hoshida et al., 2007) and in 
its own right results in infections like pneumocystis pneumonia, a common 
occurrence with HIV infection, the safety of MTX, as the “anchor” drug for RA needs 
to be systematically investigated in HIV patients with RA.  
 
Another important observation in the present study was that in spite of improvement 
in all clinical parameters and the CRP following HIV seroconversion, the ESR 
showed no change. In fact, the mean ESR was numerically higher at TL compared to 
T0, but this did not reach statistical significance. This had a direct impact on DAS28-
ESR, such that at T0 there was no statistical difference between the DAS28-CRP and 
DAS28-ESR, but the mean DAS28-ESR being significantly higher than the DAS28-
CRP at both TH and TL. Compared to the DAS28-CRP, the DAS28-ESR 
overestimated disease by more than 30%. These findings suggest that in patients 
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with HIV and RA, the DAS28-ESR is not a reliable measure of overall disease 
activity. 
The mechanism behind an elevated ESR probably stems from the 
hypergammaglobulinemia (Ndakotsu et al., 2009). With the decrease in number of 
CD4 cells, comes with it a shift to anti-inflammatory cytokines, IL-4 and IL-10, which 
up regulate humoral immunity and the production of immunoglobulins. The non-
specific hypergammaglobulinemia is caused by increases of IgA, IgM and beta 2-
microglobulin (Schwartlander et al., 1993) and this results in an elevated ESR value 
which has been shown to be predictive of HIV status (Modjarrad et al., 2005). The 
ESR is also influenced by other factors such as plasma proteins, age, sex, 
rheumatoid factor, and anaemia (Talstad et al., 1983).  These may all lead to an 
elevated ESR value, thereby overestimating DAS28-ESR score and overall RA 
disease activity. CRP seems less effected by the above mentioned factors and has 
been proven to reflect more short-term disease activity changes, where as ESR 
reflects activity over a longer period. A longitudinal study from Japan comparing 
DAS28-ESR to DAS28-CRP showed that the latter underestimates disease activity 
compared to the former (Matsui et al., 2007). But in the setting of HIV, Schleicher et 
al also found that the clinical utility of ESR in the diagnosis of co-infections, such as 
tuberculosis or Streptococcus pneumonia, was poor compared to the CRP because 
of the non-specific elevation of ESR (Schleicher et al., 2005).  
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As with any retrospective studies there are potentially numerous limitations that need 
to be taken into consideration. There was incomplete patient clerking notes leading to 
missing data at some time points. Better control group selection matched for not only 
age and sex, but disease duration as well, would have strengthened the data. The 
incomplete data with respect to the CD4 count and HIV viral load meant that it was 
not possible to analyse the relationship of these parameters with disease remission. 
A critical component in the DAS scores is the tender and swollen joint counts and it is 
well known that there is inter-observer variability among different physicians, which 
also needs to be taken into consideration (Grunke et al., 2010). Too few of our 
patients were on HAART to give a comment on disease activity response to 
improving immune status.   
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CHAPTER 5:  CONCLUSION 
Up until the end of 2008, there was a 4.9 % incidence of HIV amongst the RA 
patients in the Rheumatology Unit at Chris Hani Baragwanath Academic Hospital. 
Among patients who contracted HIV infection after the diagnosis of RA, disease 
activity overall improved with HIV seroconversion, which was sustained in the 
absence of MTX treatment. In spite of the overall improvement in disease activity, 
there remains an unmet need with respect to the safety of DMARD therapy in HIV 
patients with ongoing disease activity. The DAS28-ESR is a less reliable measure of 
disease activity than the DAS28-CRP because of the non-specific increase in ESR 
with HIV infection.  
Further work is needed on 1) relationships of the CD4 cell count and viral load to RA 
disease activity; 2) effect of HAART on disease activity in RA; 3) safety of DMARDs 
and HIV infection and; 4) predictors of RA remission in HIV patients. 
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